Galmed Pharma (GLMD) Tops Q3 EPS by 3c

Galmed Pharma (NASDAQ: GLMD) reported Q3 EPS of ($0.23), $0.03 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $300 thousand versus the consensus estimate of $330 thousand.

For earnings history and earnings-related data on Galmed Pharma (GLMD) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Wells Fargo cuts Netflix rating on engagement risk, weak slate
• Investing.com’s stocks of the week